SCHEMBL347288

SCHEMBL347288

Cc1nc(-n2c(=O)[nH]c3ccccc32)sc1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 7/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
GABRP O00591 4/20 0.44
GABRD O14764 4/20 0.44
GABRA1 P14867 4/20 0.44
GABRB1 P18505 4/20 0.44
GABRG2 P18507 4/20 0.44
GABRB3 P28472 4/20 0.44
GABRA5 P31644 4/20 0.44
GABRA3 P34903 4/20 0.44
GABRA2 P47869 4/20 0.44
GABRB2 P47870 4/20 0.44
GABRA4 P48169 4/20 0.44
GABRE P78334 4/20 0.44
GABRA6 Q16445 4/20 0.44
GABRG1 Q8N1C3 4/20 0.44
GABRG3 Q99928 4/20 0.44
GABRQ Q9UN88 4/20 0.44
PIK3CD O00329 1/20 0.42
PIK3CA P42336 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL348977 0.84 MEN1 (0.53) AURKASMN1; SMN2KDM4EKMT2A
SCHEMBL17845556 0.74 PARG (0.53) AURKAGABRPGABRDGABRA1GABRB1
SCHEMBL17845363 0.73 AURKA (0.51) AURKAGABRPGABRDGABRA1GABRB1
SCHEMBL31121978 0.73 AURKA (0.51) AURKAGABRPGABRDGABRA1GABRB1
SCHEMBL244654 0.70 PIK3CD (0.46) SMN1; SMN2PIK3CDPIK3CAPIK3CBKDM4E
SCHEMBL348510 0.69 SCD (0.51)
SCHEMBL21464011 0.69 PARP1 (0.53) AURKAGABRPGABRDGABRA1GABRB1
SCHEMBL30615405 0.69 HSP90AA1 (0.52) AURKAGABRPGABRDGABRA1GABRB1
SCHEMBL242203 0.68 SCD (0.52) SMN1; SMN2PIK3CDPIK3CAPIK3CBKDM4E
SCHEMBL187393 0.68 XDH (0.48) SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318949-B2 Organic compounds NOVARTIS AG (CH) 2012-11-27 US disclosed
US-20120014906-A1 ORGANIC COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2012-01-19 US disclosed
US-8049016-B2 Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes NOVARTIS AG (CH) 2011-11-01 US disclosed
US-20090264444-A1 Organic compounds XENON PHARMACEUTICALS INC. (CA) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120014906-A1 ORGANIC COMPOUNDS SCD, SCD5, FADS2 AURKA 2161/4885SMN1; SMN2 3581/4885GABRP 2268/4885
US-20090264444-A1 Organic compounds SCD, SCD5, FADS2 AURKA 2161/4885SMN1; SMN2 3581/4885GABRP 2268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.